



IFW

ATTORNEY DOCKET NO. 059490-5042

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Inventors: Anders PETTERSSON et al.)	
)	
Application No.: 10/531,598)	Group Art Unit: 1615
)	
Filed: November 25, 2005)	Examiner: unassigned
)	
For: GASTRIC ACID SECRETION INHIBITING)	
COMPOSITION)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
Customer Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

The Examiner is requested to consider the attached in the examination of this application. Copies of the listed references are included except for U.S. patents.

A similar disclosure submission is being filed in the applicants' related Appln. No. 11/544,750.

The return of an initialed copy of the attached PTO-1449 indicating the Examiner's consideration is requested.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If it should be determined that the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Applicants further reserve the right to take

appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 50-0310.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP




Paul N. Kokulis, Reg. No. 16,773

Date: April 11, 2007

Customer No. 09629
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Phone: (202) 739-3000
Facsimile: (202) 739-3001
Direct: (202) 739-5455

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

M#

Client Ref.

059490-5042

ORECZ/P32872US

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Anders PETTERSSON et al.

Appln. No.: 10/531,598

Filing Date: November 25, 2005

Date: April 11, 2007

Page 1 of 2

Examiner: unassigned

Group Art Unit: 1615

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR 4,283,408	08/1981	Hirata et al.	424	270	
	BR 5,244,670	09/1993	Upson et al.	242	439	
	CR 5,840,737	11/1998	Phillips	514	338	
	DR 6,013,680	01/2000	Ogawa et al.	514	925	
	ER 6,489,346 B1	12/2002	Phillips	514	338	
	FR 6,645,988 B2	11/2003	Phillips	514	338	
	GR 6,699,885 B2	03/2004	Phillips	514	338	
	HR 2004/0171646 A1	09/2004	Phillips	514	338	
	IR 2005/0054682 A1	03/2005	Phillips	514	338	

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	JR WO 98/40054	09/1998	WIPO	Wendsjö	A61K	X			
	KR 0 338 861	10/1989	Europe	Spickett et al.	A61K	X			
	LR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

MR	Gschwantler et al., "Famotidine versus orneprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori – a randomized, controlled trial", Ailment Pharmacol Ther, 13:1063-1069 (1999)	X			
NR	Eriksson et al., "Omeprazole and H ₂ -receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis", European Journal of Gastroenterology & Hepatology, 7(5):467-475 (1995)	X			
OR	Hedenström et al., "Intragastric pH after oral administration of single doses of ranitidine effervescent tablets, omeprazole capsules and famotidine fast-dissolving tablets to fasting healthy volunteers", Ailment Pharmacol Ther, 11:1137-1141 (1997)	X			
PR	Hurlimann et al., "Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole", Ailment Pharmacol Ther, 8:193-201 (1994)	X			
QR	Hunyady et al., "Statistical interpretation of the antisecretory effect of famotidine measured by intragastric pH-metry", Eur. J. Clin. Pharmacol., 50:449-456 (1996)	X			

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.		
				059490-5042		ORECZ/P32872US		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Applicant: Anders PETTERSSON et al.				
				Appln. No.: 10/531,598				
				Filing Date: November 25, 2005				
				Examiner: unassigned		Group Art Unit: 1615		
Date: April 11, 2007 Page 2 of 2								
U.S. PATENT DOCUMENTS								
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)		Class	Sub Class	Filing Date (if appropriate)
	RR							
	SR							
	TR							
	UR							
FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available
		Document Number	Date MM/YYYY	Country	Inventor Name			
	VR							
	WR							
	XR							
	YR							
OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
	ZR	Hoogerwerf et al., "Agents Used for Control of Gastric Acidity and Treatment of Peptic Ulcers and Gastroesophageal Reflux Disease", Goodman & Gilman's, The Pharmacological Basis of Therapeutics (Tenth Edition) McGraw-Hill, published September 2001, pp. 1005-1020				X		
	AAR							
	BBR							
	CCR							
Examiner					Date Considered:			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								